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Abstract
Background Anorectal pain is a symptom which may have both structural and functional causes, and can, sometimes, develop 
into a chronic pain syndrome. Functional causes in particular are challenging to treat when conservative treatment measures 
fail. Botulinum toxin A (BTX-A) can be applied to relax the anal sphincter and/or levator ani muscle to break the vicious 
circle of pain and contraction. In our tertiary referral proctology clinic, we evaluated the outcome of patients treated with 
BTX-A for chronic functional anorectal pain.
Methods Our electronic database was searched for patients who had BTX-A treatment for chronic functional anorectal 
pain from 2011 to 2016. All medical data concerning history, treatments, and clinical outcome were retrieved. The clinical 
outcome (resolution of pain) was scored as good, temporary, or poor.
Results A total of 113 patients [47 (42%) males; age 51years, SD 13 years, range 18–88 years] with chronic functional 
anorectal pain were included. The outcome of BTX-A treatment was good in 53 (47%), temporary in 23 (20%), and poor 
in 37 (33%). To achieve this outcome, 29 (45%) patients needed a single treatment, 11 (44%) a second treatment, and 13 
(54%) ≥ 3 treatments.
Conclusions Chronic functional anorectal pain can be treated successfully with BTX-A in 47% of patients who fail conserva-
tive management. Repeated injections may be needed to ensure complete cure in a subgroup of patients.
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Introduction
Anorectal pain is a symptom with a negative impact on the 
quality of life, and can sometimes develop into a chronic 
pain syndrome [1]. The etiology can generally be divided 
into two groups: (1) structural disorders, such as anal fis-
sures, fistulas, or hemorrhoids, disorders often associated 
with infection, thrombosis, or necrosis which can subse-
quently lead to pain, and (2) functional disorders, such as 
levator ani syndrome (LAS) and unspecified anorectal pain 
[2]. Structural disorders are treated according to their under-
lying pathology and functional disorders initially with con-
servative measures such as life style, diet, fibres, laxatives, 
and pelvic floor physiotherapy. When conservative measures 
fail, functional disorders can be challenging to treat.
Functional disorders associated with chronic anorec-
tal pain as defined by the Rome IV criteria [3] are LAS, 
unspecified anorectal pain, and proctalgia fugax [2]. LAS is 
described as an episode of anorectal pain of unclear etiology, 
originating in the levator ani muscle. The levator ani muscle 
is painful during palpation in patients with LAS. The patho-
physiology has been related to a hypertonic pelvic floor [2]. 
Treatments have been unsatisfactory to date, and botulinum 
toxin A (BTX-A) injections have been applied with limited 
success [4–6]. Unspecified anorectal pain does not cause 
any specific tenderness in the levator ani muscle. Proctalgia 
fugax has a distinct pain pattern and lies beyond the scope 
of this study. Both structural and functional disorders can 
lead to pelvic floor dyssynergia (PFD), sometimes called 
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anismus. Patients with PFD typically present with defeca-
tion difficulties, such as anorectal pain, prolonged straining, 
frequent attempts to have a bowel movement and a feeling of 
incomplete evacuation [5]. The diagnosis of PFD is essen-
tially a clinical diagnosis. Digital rectal examination shows 
the failure of relaxation or hypertonic state of the external 
anal sphincter and puborectal muscle during evacuation [7]. 
According to the Rome IV criteria, additional tests are rec-
ommended to confirm the diagnosis; two out of three of bal-
loon expulsion test, defecography, electromyography of the 
external anal sphincter and puborectal muscle, or anorectal 
manometry, should be indicative, although the criteria for 
the latter are not precisely defined [5].
Pelvic floor dyssynergia can be a primary disorder that 
leads to anorectal pain, but it can also develop secondary to 
disorders causing anorectal pain. The vicious circle of pain 
and increased tension of the external anal sphincter and leva-
tor ani muscle can lead to even more pain. Patients with PFD 
are first treated with lifestyle modification, pharmacological, 
behavioural, and pelvic floor physical therapy including bio-
feedback. When these treatments are unsuccessful, BTX-A 
may be offered, although its success has been shown to be 
limited [4, 5].
BTX-A is the product of the anaerobic bacterium 
Clostridium botulinum [7]. There are seven types of bot-
ulinum toxin with different antigenic properties, but all 
types share a similar structure. BTX-A binds to extracel-
lular glycoprotein structures of the presynaptic cholinergic 
nerve endings, preventing the secretion of acetylcholine, an 
excitatory neurotransmitter. The lack of acetylcholine in the 
synapse causes neuromuscular blockage and muscle paraly-
sis. BTX-A injected into the anal sphincter creates a tempo-
rary chemical denervation and injection into the levator, ani 
induces a similar effect of temporary relaxation The effects 
of BTX-A last up to 16 weeks [8]. Repeated injections can 
cause a more rapid breakdown of BTX-A due to the forma-
tion of antibodies [8, 9]. BTX-A treats the hypertonia, and, 
therefore, can help to cure structural disorders such as anal 
fissure. Subsequently, the normal muscle tone in the external 
anal sphincter and levator ani muscle can be restored, to 
break the vicious cycle.
Injection of BTX-A has provided the best results in treat-
ing anal fissure, and has been widely accepted with success 
rates up to 96% [10]. However, the literature shows conflict-
ing results on the treatment of PFD and LAS with BTX-A 
[4, 11, 12].
The aim of this study was to evaluate the use of BTX-A 
treatment in patients suffering from chronic functional ano-
rectal pain.
Materials and methods
Patients
The electronic database at the Proctos Clinic (tertiary 
referral proctology clinic, Bilthoven, The Netherlands) 
was searched for patients who had treatment with BTX-A 
for chronic anorectal pain between 2011 and 2016. 
Chronic anorectal pain was defined as pain > 3 months in 
the anus or pelvic floor according to the Rome IV criteria. 
All patients with a concomitant structural disorder at the 
time of BTX-A treatment such as an anal fissure or fistula 
were excluded. Patients who had had the previous ano-
rectal surgery, including rubber band ligation for hemor-
rhoids, were also excluded.
At the first visit, a full medical history and physical 
examination, including a routine digital rectal examina-
tion of the anal sphincters and the levator ani muscle, were 
performed. The combined results of electromyography and 
digital rectal examination provided a diagnosis of hyper-
tonia of the anal sphincter and/or levator ani muscle. The 
pain was classified as LAS when the levator ani muscle 
was painful during palpation. A classification of unspeci-
fied anorectal pain was given in the absence of a painful 
palpation of the levator ani muscle.
Before BTX-A was considered, all patients followed 
standard conservative treatment, consisting of regula-
tion of bowel movements (dietary advice; prescription of 
laxatives), pain medication (including opiates and/or pre-
gabalin or amitriptyline if necessary), and psychosomati-
cal counselling if required. All eligible patients had been 
treated with one or more of these conservative measures 
for at least 3 months. In addition, patients were seen by a 
pelvic floor physiotherapist to receive biofeedback. Elec-
tromyography of the anal sphincter and levator ani was 
performed using the MAPle® probe. This probe is able to 
distinguish muscle tone of individual pelvic floor muscles 
[13]. Physiotherapy by the pelvic floor physiotherapist was 
continued throughout treatment.
Treatment
Botulinum toxin injection procedure
Patients with hypertonia of the anal sphincter muscle 
received 2 injections of 30 units of BTX-A, and patients 
with hypertonia of the levator ani muscle 2 injections of 
40 units each. If patients suffered from hypertonia in both 
muscles, they received both treatments (2 injections of 30 
units into the anal sphincter and 2 injections of 40 units 
into the levator ani muscle). All injections were given 
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under local anesthesia with the patient in the left lateral 
position or under general anesthesia with the patient in 
lithotomy position. The skin around the anus was disin-
fected. Injections into both the anal sphincter and leva-
tor ani muscle were given under digital guidance of one 
finger which was positioned in the anus. The needle for 
injection in the anal sphincter muscle was placed laterally 
to the anus in the inter-sphincteric space and inserted up 
to 2 cm proximally to inject the BTX-A, depending on 
the length of the anal canal. The procedure was repeated 
contralaterally (3 and 9 o’clock). The needle for injec-
tion into the levator ani muscle was placed in the skin at 
3–4 cm laterally to the anus (lateral to the outer border of 
the external anal sphincter muscle) and inserted proxi-
mally with a slight deviation to the middle of the rectum. 
The levator ani muscle was hooked up with the tip of the 
finger in the anus and retracted downwards. The needle 
was then inserted into the muscle until the tip of the needle 
could be identified with palpation of the finger inside the 
rectum near to the rectal mucosa without perforating it. 
The needle was retracted slightly and BTX-A was injected. 
The procedure was repeated at the opposite site (4 and 8 
o’clock). A total of 4 different surgeons were involved in 
the care of the patients.
Follow‑up
Patients were reviewed at 3 months after BTX-A treatment. 
Those with complete resolution of their functional anorectal 
pain were discharged from further follow-up. Patients with 
an initial good response to BTX-A treatment but a relapse 
of their symptoms, or those who had no response or worsen-
ing of their symptoms were offered a repeat treatment with 
BTX-A. Patients with no response to BTX-A were offered 
up to 3 treatment cycles, and patients with an initial response 
to treatment up to 8 treatment cycles.
For analysis, patients were further divided into groups 
based on sex, number of treatments, duration of complaints, 
hypertonia of the anal sphincter, levator muscle, or both. 
Informed consent was obtained from all the individual 
patients in this study. The VU University Medical Centre 
Ethics Committee approved this study.
Outcome
The outcome of treatment was scored as good, temporary, 
or poor. Good was defined as complete resolution of pain 
and no further treatment or follow-up needed for chronic 
functional anorectal pain following BTX-A treatment. Tem-
porary was defined as the initial good response but relapse 
within 3 months. Poor was defined as no improvement, or 
even worsening of symptoms and anal pain, necessitating 
treatment with transcutaneous electrical nerve stimulation 
(TENS), or were referral to a pain specialist. Patients whose 
outcome was temporary were offered the same options after 
a relapse of their symptoms and cessation of BTX-A therapy. 
Up to 8 subsequent treatments with BTX-A were offered.
Statistical analysis
All statistical analyses were performed using SPSS (IBM, 
SPSS Statistics 22). Continuous data were described as 
mean or median depending on the distribution, with stand-
ard deviation or range, respectively. To detect differences in 
outcome between groups, the Chi-square test was performed. 
If additional testing between subgroups was performed, a 
Bonferroni correction for the p value was applied. A differ-
ence was considered significant if p < 0.05.
Results
Patient demographics
A total of 118 of eligible patients were identified, but 5 
were lost to follow-up. Thus, 113 patients were evalu-
ated. There were 47 males (42%) and the mean age was 
51 years (range 18–88 years). The mean duration of com-
plaints before the first visit to our clinic was 6 years (range 
3 months – 40 years). The mean defecation frequency was 
twice daily. 15 patients (13%) reported obstructed defecation 
concomitant with their anorectal pain.
Eleven patients (10%) were diagnosed with LAS, while 
the other 102 (90%) were found to have unspecified anorec-
tal pain. All patients had a form of hypertonia (anal sphinc-
ter: 20%, levator ani: 38%, and both muscles: 42%). Eighteen 
(16%) patients were active smokers. The median number of 
BTX-A treatments was 2 with a range of 1–8 treatments.
Outcome
Overall, the outcome was good in 53 (47%) patients, tempo-
rary in 23(20%) patients, and poor in 37 (33%) patients. Sex, 
age, smoking, or duration of complaints did not significantly 
influence the outcome. Patients with isolated hypertonia of 
the levator ani (38%) seemed to perform worse when com-
pared to patients with isolated hypertonia of the anal sphinc-
ter (20%) or a combination of hypertonia (42%), although 
these results were not statistically significant (p = 0.06). The 
number of treatments did not influence the overall outcome 
of treatment (p = 0.051), while a relatively large percent-
age of patients (39%) had a poor outcome following single 
treatment with BTX-A. The duration of patients’ complaints 
did not seem to influence the overall outcome (p = 0.18), 
although the proportion of good outcomes among patients 
242 Techniques in Coloproctology (2019) 23:239–244
1 3
with longstanding complaints (≥ 5 years) was substantially 
lower than among patients with a more recent onset of ano-
rectal pain (28% vs 52% and 48%). There was no difference 
in overall outcome between patients diagnosed with unspeci-
fied anorectal pain or LAS (p = 0.72). The results are shown 
in Table 1. Two patients had temporary fecal incontinence 
following treatment. No other adverse effects were noted.
Discussion
In this study, treatment with BTX-A provided a sustained 
cure in 47% of patients suffering from chronic functional 
anorectal pain. An additional 20% had an initial response 
to treatment, but relapsed within 3 months. Factors like sex, 
age smoking, and psychiatric history did not influence out-
come. However, these subgroups were small, so no firm con-
clusions could be drawn. Patients with the isolated hyper-
tonia of the levator ani seem to perform worse than those 
with solely hypertonia of the anal sphincter or a combination 
of both, but these results were not statistically significant 
(p = 0.06). The anorectal pain in patients suffering from 
hypertonia in both muscles might have been caused only by 
the hypertonic state of the anal sphincter, which could pos-
sibly respond better to treatment with BTX-A.
Of 11 patients with LAS, 5 achieved a sustained relief of 
symptoms following BTX-A treatment. No more than three 
treatments were given to these patients to achieve this result. 
We found similar results in a study performed by Bibi et al. 
[10]. Interestingly, Rao and colleagues found that BTX-A 
treatment for LAS was not able to relieve pain in any of their 
patients [11]. We believe that our combined approach of 
continuous pelvic floor physiotherapy and BTX-A treatment 
is beneficiary for patients suffering from LAS.
While, in this study, we focused on anorectal pain, many 
patients in our study might have had PFD, but we did not 
perform the additional diagnostic tests to confirm PFD 
according to the Rome IV criteria. Anal manometry is com-
monly performed to diagnose PFD; however, patterns that 
are regarded to be abnormal can often be found in healthy 
Table 1  Results of BTX-A 
treatment in patients with 
chronic functional anorectal 
pain
*Compared to patients without stated condition
BTX-A botulinum toxin A, LAS levator ani syndrome
Number of 
patients (%)
Good n (%) Temporary n (%) Poor n (%) Chi-square
P value
All patients 113 (100) 53 (47) 23(20) 37 (33) –
Sex
 Male 47 (42) 24 (51) 8 (17) 15 (32) 0.69
 Female 66 (58) 29 (44) 15 (23) 22 (33)
Age in years
 18–49 55 (49) 28 (51) 11 (20) 16 (29) 0.67
 50 < 58 (51) 25 (43) 12 (21) 21 (36)
Psychiatric history 12 (11) 8 (66) 2 (17) 2 (17) 0.32*
Smoking 18 (16) 8 (44) 3 (17) 7 (39) 0.81*
Inducing factor known 32 (28) 16 (50) 7 (22) 9 (28) 0.81
Hypertonia
 Sphincter 23 (20) 15 (65) 2 (9) 6 (26) 0.06
 Levator ani 43 (38) 13 (32) 12 (32) 18 (36)
 Both 47 (42) 25 (53) 9 (19) 13 (28)
Number of treatments
 1 64 (57) 29 (45) 10 (16) 25 (39) 0.051
 2 25 (22) 11 (44) 10 (40) 4 (16)
 3 or more 24 (21) 13 (54) 3 (13) 8 (33)
Duration of complaints
 < 1 year 21 (26) 10 (48) 3 (14) 8 (38) 0.18
 1–5 years 31 (38) 16 (52) 4 (13) 11 (35)
 5 or more 29 (36) 8 (28) 10 (34) 11 (38)
Diagnosis
 LAS 11 (10) 5 (46) 3 (27) 3 (27) 0.82
 Unspecified anorectal pain 102 (90) 48 (47) 20 (20) 34 (33)
Obstructed defecation 15 (13) 7 (47) 2 (13) 6 (40) 0.72*
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volunteers [14]. A digital rectal examination has a high sen-
sitivity as well as positive predictive value as a diagnostic 
tool in disorders like PFD, if performed by an experienced 
clinician [15]. Illustrative of the possible effect of BTX-A 
treatment on PFD are our 15 patients (13%) that reported 
the symptoms of obstructed defecation as well as anorec-
tal pain. Seven of these patients (47%) achieved sustained 
resolution not only of their anorectal pain, but also their 
defecation difficulties. A direct comparison with the study 
by Emile et al. [4] is not feasible, because we only evalu-
ated the resolution of pain, and did not meet the criteria to 
diagnose PFD according to the Rome IV criteria. However, 
resolution of pain might allow these patients to relearn nor-
mal defecation behaviour, under the supervision of a pelvic 
floor physiotherapist.
Patients whose symptoms initially improved but who 
had a recurrence of their anorectal pain, or showed no 
improvement, were offered repeated injections after 
3 months. Repeated treatment seems to be effective in some 
patients, which suggests that, sometimes, injections need 
to be repeated to achieve a better outcome. Patients with 
longstanding anorectal pain had remarkably less sustained 
response (28%), although this was not statistically significant 
in overall outcome (p = 0.18). This may in part be due to 
the development of behavioural changes and sensitisation 
[1, 16]. Early application of BTX-A treatment in patients 
with chronic functional anorectal pain might provide a better 
chance at a sustained resolution of their pain.
In this study, a standard dose of 60, 80, or 140 units of 
BTX-A was given to each patient based on hypertonia of 
the anal sphincter and/or levator ani muscle. A recent meta-
analysis suggests that a low dose of BTX-A is just as effec-
tive as a higher dose when treating an anal fissure, but is 
associated with fewer complications and side effects [17]. In 
contrast, a recently published retrospective cohort study with 
158 patients not included in the meta-analysis found a higher 
dose to be more effective, with no difference in side effects 
[18]. These results might indicate that dosing could still be 
further optimized, especially for patients suffering from 
unspecified chronic anorectal pain or LAS. Moreover, we 
found that only 2 patients developed temporary fecal inconti-
nence, and no other adverse events were reported, indicating 
that BTX-A treatment is a relatively safe procedure.
The strengths of this study are the large patient popula-
tion, and the experienced team in a specialized referral cen-
tre for proctology. Furthermore, our results show that con-
tinuation of physiotherapy may have led to success, because 
it gave the patient increased awareness of pelvic floor physi-
ology. Limitations are the retrospective nature of the study 
and the lack of an explicit patient-related outcome meas-
urement (PROM) or visual analogue scale (VAS). There 
are very few studies reporting on the treatment of chronic 
functional anorectal pain and outcome is generally scored 
as clinical response. We believe more prospective studies 
evaluating the effect of BTX-A treatment in chronic func-
tional anorectal pain are warranted to investigate whether 
BTX-A treatment should be implemented in the protocol for 
the treatment of patients with this condition. Furthermore, a 
validated patient-related outcome score should be developed 
to validate and interpret results found in future studies.
Conclusions
Treatment with BTX-A is a safe and reasonably effec-
tive treatment for chronic functional anorectal pain. It can 
provide a sustained resolution of anorectal pain in 47% 
of patients who are refractory to conservative measures. 
Repeated treatments with BTX-A after initial treatment 
failure can still provide a sustained cure in up to 50% of 
patients. Patients with longstanding duration of anorectal 
pain might respond less to BTX-A treatment. Patients with 
anorectal pain should be offered BTX-A treatment after 
3–6 months to prevent the development of chronic pain 
by behavioural changes, sensitisation, and to minimise the 
impact on daily activities. Patients need to be made aware 
that anal pain leads to paradoxical contraction of the levator 
ani muscle and that this might be the onset of the develop-
ment of chronic anal pain. Continuing pelvic floor therapy 
after BTX-A may be of added value.
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